What is the typical source of Klebsiella bacteremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The typical source of Klebsiella bacteremia is the gastrointestinal tract, particularly the colon, where Klebsiella species naturally colonize, as well as urinary tract infections, especially in patients with indwelling urinary catheters or those with urinary tract abnormalities, and respiratory infections, including hospital-acquired pneumonia, particularly in immunocompromised patients or those on mechanical ventilation. According to the most recent evidence from 1, the management of infections caused by multidrug-resistant bacteria, including Klebsiella, should prioritize the use of novel β-lactam agents such as ceftazidime/avibactam and meropenem/vaborbactam as first-line treatment options for infections caused by KPC-producing carbapenem-resistant Enterobacterales (CRE). Some key points to consider in the management of Klebsiella bacteremia include:

  • The gastrointestinal tract, urinary tract, and respiratory tract are common sources of infection
  • Risk factors for developing Klebsiella bacteremia include diabetes mellitus, alcoholism, malignancy, and prolonged hospitalization
  • Empiric therapy often includes broad-spectrum antibiotics such as carbapenems, with therapy narrowed based on susceptibility testing results
  • The use of ceftazidime/avibactam and meropenem/vaborbactam is recommended for the treatment of infections caused by KPC-producing CRE, with consideration of the site of infection and local epidemiology
  • Imipenem/relebactam and cefiderocol may also be considered as potential alternatives for the treatment of infections involving KPC-producing CRE, although clinical studies of their efficacy in these patients are limited. It is essential to note that the management of Klebsiella bacteremia should be guided by the most recent and highest-quality evidence, and that local epidemiology and resistance patterns should be taken into account when selecting empiric therapy.

From the Research

Typical Source of Klebsiella Bacteremia

The typical source of Klebsiella bacteremia can vary, but some common sources include:

  • Urinary tract infections (UTIs) 2, 3
  • Pneumonia 2, 4
  • Intra-abdominal infections 5, 6
  • Catheter-associated urinary tract infections (CAUTIs) 3

Community-Acquired vs. Hospital-Acquired Infections

Community-acquired Klebsiella bacteremia (CAKB) and hospital-acquired Klebsiella bacteremia (HAKB) have different underlying sources:

  • CAKB: often associated with UTIs (58% of cases) 2
  • HAKB: often associated with pneumonia (25% of cases) and more likely to result in serious manifestations of illness, such as shock and respiratory failure 2

Virulence Factors and Molecular Epidemiology

Klebsiella pneumoniae strains can exhibit various virulence factors, including:

  • Adhesive fimbriae
  • Capsule
  • Lipopolysaccharide (LPS)
  • Siderophores or iron carriers 3, 4 These factors contribute to the pathogenicity of K. pneumoniae and can lead to the development of antibiotic-resistant strains.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Klebsiella bacteraemia: community versus nosocomial infection.

QJM : monthly journal of the Association of Physicians, 1996

Research

Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.